Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many
metastatic cancers. However, the single-agent efficacy of ICIs in breast cancer is low …

Highlights•TNBCs is one of the most heterogenous form of breast cancer appear to have
elevated numbers of immune cells infiltration.•Using immune checkpoint inhibitors (ICIs) …

Breast cancer has historically been a disease for which immunotherapy was largely
unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with …

Simple Summary For decades, countless efforts have been devoted to developing targeted
drugs to improve the prognosis of triple-negative breast cancer (TNBC). Among the novel …

The development of immunotherapy agents has revolutionized the field of oncology. The
only FDA-approved immunotherapeutic approach in breast cancer consists of immune …

Introduction Immune checkpoint inhibitor (ICI) monotherapy appears to be effective in a
small cohort of patients with metastatic triple negative breast cancer (mTNBC). This supports …

Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery,
radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the …

The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has
revolutionized the treatment of solid tumor malignancies. In breast cancer, the most robust …

The widespread adoption of immunotherapy has revolutionized the treatment of various
cancer types, including metastatic triple-negative breast cancer (TNBC), which has long …

Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …